[1]
Bostwick, D.G.; Cooner, W.H.; Denis, L.; Jones, G.W.; Scardino, P.T.; Murphy, G.P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer, 1992, 70(Suppl. 1), 291-301.
[2]
Alcaraz, A.; Hammerer, P.; Tubaro, A.; Schröder, F.H.; Castro, R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur. Urol., 2009, 55(4), 864-873.
[3]
Ørsted, D.D.; Bojesen, S.E. The link between benign prostatic hyperplasia and prostate cancer. Nat. Rev. Urol., 2013, 10(1), 49-54.
[4]
Miah, S.; Catto, J. BPH and prostate cancer risk. Indian J. Urol., 2014, 30(2), 214-218.
[5]
Bespalov, V.G.; Kuzhanov, A.A.; Vasilieva, I.N.; Semenov, A.L.; Alexandrov, V.A. Relationship between benign prostatic hyperplasia and prostate cancer: New opportunities for prostate cancer chemoprevention. Vopr. Onkol., 2016, 62(2), 360-371.
[6]
Chokkalingam, A.P.; Nyrén, O.; Johansson, J.E.; Gridley, G.; McLaughlin, J.K.; Adami, H.O.; Hsing, A.W. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: A population-based cohort study in Sweden. Cancer, 2003, 98(8), 1727-1734.
[7]
Ørsted, D.D.; Bojesen, S.E.; Nielsen, S.F.; Nordestgaard, B.G. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: A nationwide cohort study of 3, 009, 258 men. Eur. Urol., 2011, 60(4), 691-698.
[8]
Jun, J.E.J.; Kinkade, A.; Tung, A.C.H.; Tejani, A.M. 5α-Reductase inhibitors for treatment of benign prostatic hyperplasia: A systematic review and meta-analysis. Can. J. Hosp. Pharm., 2017, 70(2), 113-119.
[9]
Thompson, I.M.; Klein, E.A.; Lippman, S.M.; Coltman, C.A.; Djavan, B. Prevention of prostate cancer with finasteride: US/European perspective. Eur. Urol., 2003, 44(6), 650-655.
[10]
Andriole, G.L.; Bostwick, D.G.; Brawley, O.W.; Gomella, L.G.; Marberger, M.; Montorsi, F.; Pettaway, C.A.; Tammela, T.L.; Teloken, C.; Tindall, D.J.; Somerville, M.C.; Wilson, T.H.; Fowler, I.L.; Rittmaster, R.S. REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med., 2010, 362(13), 1192-1202.
[11]
Aceves, C.; Anguiano, B.; Delgado, G. The extrathyronine actions of iodine: antioxidant, apoptotic and differentiator factor in iodine uptake tissues. Thyroid, 2013, 23(8), 938-946.
[12]
De la Vieja, A.; Santisteban, P. Role of iodide metabolism in physiology and cancer. Endocr. Relat. Cancer, 2018, 25(4), 225-245.
[13]
Nakatsuka, H.; Chiba, K.; Watanabe, T.; Sawatari, H.; Seki, T. Iodine intake by adult residents of a farming area in Iwate Prefecture, Japan, and the accuracy of estimated iodine intake calculated using the standard tables of food composition in Japan. Environ. Health Prev. Med., 2016, 21(6), 523-530.
[14]
Katagiri, R.; Asakura, K.; Sasaki, S.; Hirota, N.; Notsu, A.; Miura, A.; Todoriki, H.; Fukui, M.; Date, C. Estimation of habitual iodine intake in Japanese adults using 16 d diet records over four seasons with a newly developed food composition database for iodine. Br. J. Nutr., 2015, 114(4), 624-634.
[15]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[16]
Savchik, S.A.; Zhukova, G.F.; Lublinskii, S.L. The study of physico-chemical properties of iodinated proteins for iodine deficiency prophylaxis. Vopr. Pitan., 2005, 74(4), 3-8.
[17]
Scolnik, M.D.; Servadio, C.; Abramovici, A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J. Androl., 1994, 15(4), 287-297.
[18]
Kulikovskii, A.V.; Lisitsyn, A.B.; Chernukha, I.M.; Gorlov, I.F.; Savchuk, S.A. Determination of iodotyrosines in food. J. Anal. Chem., 2016, 71(12), 1215-1219.
[19]
Bolshakova, L.S.; Lisitsyn, A.B.; Chernukha, I.M.; Zubtsov, Y.N.; Lukin, D.E.; Lyublinsky, S.L. The study of the metabolism of iodotyrosines included in the iodized milk protein in rats. Vopr. Pitan., 2018, 87(4), 12-17.
[20]
Quintero-García, M.; Delgado-González, E.; Sánchez-Tusie, A.; Vázquez, M.; Aceves, C.; Anguiano, B. Iodine prevents the increase of testosterone-induced oxidative stress in a model of rat prostatic hyperplasia. Free Radic. Biol. Med., 2018, 115, 298-308.
[21]
Minciullo, P.L.; Inferrera, A.; Navarra, M.; Calapai, G.; Magno, C.; Gangemi, S. Oxidative stress in benign prostatic hyperplasia: A systematic review. Urol. Int., 2015, 94(3), 249-254.
[22]
Roumeguère, T.; Sfeir, J.; El Rassy, E.; Albisinni, S.; Van Antwerpen, P.; Boudjeltia, K.Z.; Farès, N.; Kattan, J.; Aoun, F. Oxidative stress and prostatic diseases. Mol. Clin. Oncol., 2017, 7(5), 723-728.
[23]
Navarra, M.; Micali, S.; Lepore, S.M.; Cesinaro, A.M.; Celano, M.; Sighinolfi, M.C.; De Gaetani, C.; Filetti, S.; Bianchi, G.; Russo, D. Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology, 2010, 75(4), 773-778.
[24]
Aranda, N.; Sosa, S.; Delgado, G.; Aceves, C.; Anguiano, B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. Prostate, 2013, 73(1), 31-41.
[25]
Olvera-Caltzontzin, P.; Delgado, G.; Aceves, C.; Anguiano, B. Iodine uptake and prostate cancer in the TRAMP mouse model. Mol. Med., 2013, 19, 409-416.
[26]
Gupta, S.; Adhami, V.M.; Subbarayan, M.; MacLennan, G.T.; Lewin, J.S.; Hafeli, U.O.; Hafeli, U.O.; Fu, P.; Mukhtar, H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 2004, 64(9), 3334-3343.
[27]
Bonorden, M.J.; Grossmann, M.E.; Ewing, S.A.; Rogozina, O.P.; Ray, A.; Nkhata, K.J.; Liao, D.J.; Grande, J.P.; Cleary, M.P. Growth and progression of TRAMP prostate tumors in relationship to diet and obesity. Prostate Cancer, 2012, 2012543970
[28]
Nguewa, P.A.; Calvo, A. Use of transgenic mice as models for prostate cancer chemoprevention. Curr. Mol. Med., 2010, 10(8), 705-718.
[29]
Xu, K.; Ling, M.T.; Wang, X.; Wong, Y.C. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia. Prost Cancer Prostatic Dis., 2006, 9(3), 293-297.
[30]
HoptionCann. S.A.; Qiu, Z.; van Netten, C. A prospective study of iodine status, thyroid function, and prostate cancer risk: Follow-up of the first national health and nutrition examination survey. Nutr. Cancer, 2007, 58(1), 28-34.